Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02956213 · ClinicalTrials.gov registry record · NA
Indoor Air Quality and Respiratory Symptoms in Former Smokers
A NA study of Chronic Obstructive Pulmonary Disease, sponsored by Intermountain Health Care.
- Completed
- Registry status
- NA
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT02956213: Completed NA study of Chronic Obstructive Pulmonary Disease, sponsored by Intermountain Health Care.
NCT02956213 is a NA study of Chronic Obstructive Pulmonary Disease that has completed, run by Intermountain Health Care. The registered enrollment target is 52 participants, below the 1,753-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02956213, a NA study of Chronic Obstructive Pulmonary Disease, has completed, sponsored by Intermountain Health Care.
- COMPLETED
- Registry status
- NA
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators will conduct a randomized, controlled, double-blind, crossover trial to determine whether the presence of a portable high-efficiency indoor air filter in the bedroom reduces respiratory symptoms in former smokers compared with placebo. The primary outcomes will be change in St. George's Respiratory Questionnaire - COPD (SGRQ-C) score associated with using a portable high-efficiency indoor air filter during the study period. Secondary outcomes of COPD exacerbations and hospitalizations, daily step counts, medication changes, spirometry, and cardiovascular outcomes will also be assessed.
Primary Outcome
based on St. George's Respiratory Questionnaire - COPD - SGRQ-C score
Conditions Studied
Interventions
- OTHER HEPA portable air filter
- OTHER Sham Control/Active Comparator
Study Locations (1)
Utah
- Intermountain Medical Center - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2016-11 |
| Est. Completion | 2019-06 |
| Phase | NA |
What the finished NCT02956213 record still lists
NCT02956213 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 1,753-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 2 interventions - of which HEPA portable air filter is the first listed.
NCT02956213 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT02956213 about?
NCT02956213 is a clinical study titled "Indoor Air Quality and Respiratory Symptoms in Former Smokers". The investigators will conduct a randomized, controlled, double-blind, crossover trial to determine whether the presence of a portable high-efficiency indoor air filter in the bedroom reduces respiratory symptoms in former smokers compared with placebo. The primary outcomes will be change in St. Geo...
What is the current status of trial NCT02956213?
This trial is currently completed. It is a NA study. The enrollment target is 52 participants. The study started on 2016-11. Estimated completion is 2019-06.
What conditions does trial NCT02956213 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease.
What interventions are being tested in trial NCT02956213?
The interventions under investigation include: HEPA portable air filter (OTHER), Sham Control/Active Comparator (OTHER).
Who is sponsoring clinical trial NCT02956213?
This trial is sponsored by Intermountain Health Care, which has 85 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02956213 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02956213's enrollment target sits among peer trials
52 62nd of 86 higher than 25 of 86 other Chronic Obstructive Pulmonary Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Obstructive Pulmonary Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mindful Steps 2.0: Promoting Physical Activity in Patients With COPD and HF
RECRUITING · NA
-
Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD
RECRUITING · NA
-
Functional Improvement in OSA and COPD With a Telehealth LifeStyle and Exercise Intervention
RECRUITING · NA
-
Improving Participation in Pulmonary Rehabilitation Through Peer Support and Storytelling
RECRUITING · NA
-
PRagmatic EVAluation of a Quality Improvement Program for People Living With Modifiable High-risk COPD.
RECRUITING · NA
-
The Increase of Lung Capacity Using the Lung Master (Pulmonary Exerciser)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia